Results 91 to 100 of about 6,306 (210)

DDIapp—A Web‐Based Application for Static Drug–Drug Interaction Assessment

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 8, August 2026.
ABSTRACT In this work we describe the development of a web‐based application for static drug–drug interaction (DDI) risk assessment in accordance with the International Council for Harmonization (ICH) M12 guidance. The app was built using the Shiny for Python framework and it employs a modular mathematical modeling structure that incorporates models ...
Hirotaka Watase, Sylvie Klieber, Yorgos M. Psarellis, Nikhil Pillai, Panteleimon D. Mavroudis, Saroj Dhakal   +5 more
wiley   +1 more source

Application of Population‐Based Meta‐Heuristic Algorithms for Robust Initialization in Mechanistic Pharmacometric Modeling

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 8, August 2026.
ABSTRACT Mechanistic PK/PD models represent complex biological systems in which model parameters are in nonlinear, multidimensional parameter spaces and often require robust optimization informed by experimental data, making parameter estimation a critical yet challenging aspect of pharmacometric analysis.
Dongjin Lee, Chih‐Wei Lin
wiley   +1 more source

Extrapolating Vincristine‐Induced Peripheral Neuropathy From Caucasian to Kenyan Populations: Impact of Type I and Type II Selection Bias

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 8, August 2026.
ABSTRACT Vincristine is a cornerstone of pediatric chemotherapy, but its use is limited by vincristine‐induced peripheral neuropathy (VIPN). Paradoxically, African children tolerate higher vincristine doses with minimal neurotoxicity, raising questions about the pharmacological mechanisms and model generalizability across populations. In this study, we
Maddalena Centanni, Mirjam Esther van de Velde, Alwin D. R. Huitema, Gertjan L. Kaspers, Mats O. Karlsson, Lena E. Friberg   +5 more
wiley   +1 more source

Refinement of Operating Characteristics for Model‐Based TGI Metrics Decision Support to Ungate a Pivotal Trial in Oncology

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 8, August 2026.
ABSTRACT The oncology market is evolving, with an increasing number of therapeutic options making the inference of treatment benefit from early development critical. The “Go” versus “No Go” decisions from such trials usually rely on probabilities of achieving meaningful improvements (effect sizes) in endpoints like objective response rate, tailored to ...
Mathilde Marchand, Kenta Yoshida, Antonio Gonçalves, Rene Bruno, Chunze Li, Jin Y. Jin, Pascal Chanu   +6 more
wiley   +1 more source

Development of a Novel Machine Learning Method for Estimation of Life‐Long Chronic Disease Progression and Its Application to Type 2 Diabetes

Clinical and Translational Science
Individual predictions of long‐term chronic disease progression from data of limited duration provide valuable insights into estimating patient outcomes and therapeutic needs.
Yamato Sano, Ryota Jin, Hideki Yoshioka, Yuki Nakazato, Hiromi Sato, Akihiro Hisaka   +5 more
doaj   +1 more source

Bayesian Workflow for Minimal PBPK Models: Case Study of Dapagliflozin

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 8, August 2026.
ABSTRACT Numerous clinical trials (CTs) and population pharmacokinetic (PK) models have been published on dapagliflozin, an approved SGLT2 inhibitor used to treat type 2 diabetes, heart failure, and chronic kidney disease. This study proposes a Bayesian workflow for the development of minimal physiologically‐based PK models (mPBPK) that integrates all ...
Anna Mikhailova, Kirill Peskov, Gabriel Helmlinger, Victor Sokolov   +3 more
wiley   +1 more source

Model-based meta-analysis of HbA1c reduction across SGLT2 inhibitors using dose adjusted by urinary glucose excretion

Scientific Reports
This study was aimed to evaluate whether the dose–response relationship of the sodium glucose co-transporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)—canagliflozin, dapagliflozin, empagliflozin, ipragliflozin ...
Hiromi Sato, Ayana Ishikawa, Hideki Yoshioka, Ryota Jin, Yamato Sano, Akihiro Hisaka   +5 more
doaj   +1 more source

Beyond Traditional Covariates: An Interpretable Machine Learning Workflow for Improved Hybrid Pharmacometric Modeling

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 8, August 2026.
ABSTRACT Model‐informed precision dosing is often constrained by the limited generalizability of traditional population pharmacokinetic models, especially in critically ill patients. A hybrid machine learning‐population pharmacokinetic framework is proposed to improve a priori pharmacokinetic predictions by integrating real‐world clinical data.
Freek J. A. Relouw, Jort J. M. T. Lokers, Tim Preijers, Sebastiaan D. T. Sassen, Natal A. W. van Riel, Birgit C. P. Koch   +5 more
wiley   +1 more source

Relevance‐Based Score for MIPD Model Selection: Systematic Review and External Evaluation of popPK Tacrolimus Models in Adult Transplant Recipients

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 8, August 2026.
ABSTRACT Selecting the most relevant models for model‐informed precision dosing (MIPD) remains challenging, particularly when numerous population pharmacokinetic (popPK) models are available, making external evaluation of all candidates time‐ and resource‐consuming.
Samuel Baroudi, Bénédicte Franck, Jean‐Baptiste Woillard, Ntobe‐Bunkete Béni, Emmanuelle Comets, Florian Lemaitre   +5 more
wiley   +1 more source

Alternative Dosing Regimens of Tislelizumab Using a Pharmacometrics Model‐Based Approach

Clinical and Translational Science
Tislelizumab 200 mg once every 3 weeks (Q3W) is approved for the treatment of multiple cancers. We used a model‐based approach to propose three alternative dosing regimens, 150 mg Q2W, 300 mg Q4W, and 400 mg Q6W, with the aims of providing flexible ...
Ahsan Rizwan, Hugh Giovinazzo, Tian Yu, Yuying Gao, Kun Wang, Fengyan Xu, Ya Wan, Jun Wang, Srikumar Sahasranaman, Marcia Campbell, Patrick Schnell, Ramil Abdrashitov, William D. Hanley, Nageshwar Budha   +13 more
doaj   +1 more source